|Bid||0.00 x 1300|
|Ask||6.98 x 900|
|Day's Range||6.38 - 7.15|
|52 Week Range||5.03 - 25.40|
|Beta (3Y Monthly)||3.41|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||1.00|
My biggest winning trades from Wednesday on PDS Biotechnology Corp (NASDAQ: PDSB) came on a handful of pullback trades. Given that, I wanted to spend some time this week analyzing my timing on these pullback trades to illustrate how timing and the qualities of a stock play in the success and failure of a pullback strategy. Given the apparent momentum, I waited for the first pullback on rising volume and got in on the break above the $7.50 closing high.
PDS Biotechnology Corporation (“PDS Biotechnology”) (PDSB), a clinical-stage immuno-oncology company pioneering the development of multifunctional immunotherapeutic products, today announced a peer-reviewed publication supporting the novel mechanisms of action of its proprietary Versamune® platform in cancer immunotherapy. The article “Antigen Priming with Enantiospecific Cationic Lipid Nanoparticles Induces Potent Antitumor CTL Responses through Novel Induction of a Type I IFN Response” was published online on May 3, 2019 in the Journal of Immunology, and describes the way PDS’ Versamune® platform recruits and activates killer T-cells to recognize and effectively attack cancer cells while simultaneously making cancer cells more susceptible to T-cell attack.
The Berkeley Heights, New Jersey-based company said it had profit of $1.47 per share. Losses, adjusted for non-recurring gains, came to $1.07 per share. PDS Biotechnology shares have declined slightly ...
BERKELEY HEIGHTS, N.J., May 14, 2019 -- PDS Biotechnology Corporation (“PDS Biotechnology”) (Nasdaq: PDSB), a clinical-stage immuno-oncology company pioneering the development.
PDS Biotechnology Corporation (PDSB), a clinical-stage immuno-oncology company developing novel multifunctional immunotherapeutic products, today announced that Stephen Glover has been appointed to PDS’s Board of Directors, effective immediately. Mr. Glover has been appointed to serve as a member of the Board of Directors’ audit committee and compensation committee. Mr. Glover has more than 30 years of experience in the biopharmaceutical industry, specializing in developing pharmaceutical business strategies, corporate and product development, and commercialization and business optimization.